California Lawyers Association
Intellectual Property Law
Updates and events from the Intellectual Property Law Section
On May 20, 2020 the IP Section presented a webinar on recent patent cases.
Read more
Join us for the IP Institute, "Shifting Tides - Intellectual Property in a Changing World."
Read more
Santa Clara University School of Law is conducting a study to identify, understand, and provide actionable advice about the best practices for attracting and including diverse inventors in the invention and patenting process.
Read more
Topics would include a discussion of recently-issued Supreme Court decisions from the last and current term.
Read more
Shira Perlmutter will discuss the Office’s priorities and major initiatives, including how the Office is implementing changes in copyright legislation and regulation, and the modernization of copyright practice.
Read more
A major piece of copyright legislation, the Copyright Alternative in Small-Claims Enforcement Act (CASE Act), was tucked into the omnibus spending and COVID-19 relief bill passed by Congress on December 21, 2020.
Read more
This January the CLA IP Section is excited to be highlighting some of our most loved and most fascinating webinars from the past!
Read more
Since we were unable to meet in person this year, the IP Section held its first ever Shelter In Place Institute.
Read more
The epidemic of stress and burnout is affecting every sector of our society, but even more so the legal profession. A study by the American Bar Association found that over 25% of lawyers suffer from depression, 21% have a drinking problem, and 19% experience anxiety. Burnout and mental distress not only take a toll on the wellbeing of lawyers, but also make their clients, people, and businesses vulnerable, impairing decision-making, problem-solving, and risk management.
Read more
As of this writing, the United States Food and Drug Administration (“FDA”) has approved GW Pharma’s CBD drug Epidiolex for treating profound refractory pediatric epilepsy syndromes (Dravet syndrome and Lennox Gastaut syndrome) as well as for treating seizures associated with tuberous sclerosis complex (TSC) in patients one year of age or older.
Read more